Go back to News
NEWS
GA_P advises Uriach on the sale of its generics and b2b business to MCH
14 of September, 2021
Gómez-Acebo & Pombo has advised Grupo J. Uriach on the sale of its B2B business to the investment fund MCH, with the participation of a group of investors. With this transaction, Uriach completes the process of divestment in the pharmaceutical sector and sale of generics, to focus on its strategic business plan in the Consumer Healthcare (CHC) sector.
The divestment involves the sale of the two production plants owned by Grupo J. Uriach Group in Spain. On the one hand, the chemical plant (Urquima) located in Sant Fost de Campsentelles and the pharmaceutical plant in Palau-Solità i Plegamans, which currently allocates 75-80% of its production to the B2B business. The rest of this production is dedicated to CHC, which will continue to be made at this plant through a long-term strategic production agreement between Grupo J. Uriach and the new company owned by the new company. Uriach Group and the new company owned by MCH. This area has a forecast turnover of 80 million by the end of 2021. MCH’s objective is to expand its activity through new developments and R&D investment.
The sale agreement is currently subject to the approval of the competition authorities.
Lazard has been the bank advisor leading the transaction and Deloitte has acted as financial advisor.
The GA_P team was formed by Dani Marín, Carolina Posse, Estefanía Fraile and Diana Urrego, partner and associate, respectively, in the Corporate area, Iñigo Igartua and Andrea Díez de Uré, partner and associate in the Competition area, Nuria Vila, of counsel in the Tax area and Begoña Vilar, associate in the Employment area.
See complete article in Cinco Días
The divestment involves the sale of the two production plants owned by Grupo J. Uriach Group in Spain. On the one hand, the chemical plant (Urquima) located in Sant Fost de Campsentelles and the pharmaceutical plant in Palau-Solità i Plegamans, which currently allocates 75-80% of its production to the B2B business. The rest of this production is dedicated to CHC, which will continue to be made at this plant through a long-term strategic production agreement between Grupo J. Uriach and the new company owned by the new company. Uriach Group and the new company owned by MCH. This area has a forecast turnover of 80 million by the end of 2021. MCH’s objective is to expand its activity through new developments and R&D investment.
The sale agreement is currently subject to the approval of the competition authorities.
Lazard has been the bank advisor leading the transaction and Deloitte has acted as financial advisor.
The GA_P team was formed by Dani Marín, Carolina Posse, Estefanía Fraile and Diana Urrego, partner and associate, respectively, in the Corporate area, Iñigo Igartua and Andrea Díez de Uré, partner and associate in the Competition area, Nuria Vila, of counsel in the Tax area and Begoña Vilar, associate in the Employment area.
See complete article in Cinco Días
Lawyer mentioned
Daniel Marín – Partner
Carolina Posse Van Der Laat – Senior associate
See all lawyers
See less lawyers
Tipology
Deal
Press contact
Director of Business Development, Marketing and Communications
Director of Business Development, Marketing and Communications
More information about
Gómez-Acebo & Pombo
23 Feb, 2026 
PUBLICATION
03 Mar, 2026
Legal doctrine of the UPC’s Court of Appeal on the patent invalidity defence: is the way in which the ‘long arm’ is applied compatible with the UPC's own Rules of Procedure?
The Court of Appeal of the Unified Patent Court has ruled that a patent invalidity defence cannot be raised before the Unified Patent Court, with only a counterclaim being possible. This calls into question the way in which the ‘long arm’ is being applied with regard to European patents validated in States that are not party to the Agreement on a Unified Patent Court (UPCA), whether or not they are members of the European Union, since no counterclaim for revocation or plea of invalidity as a defence can be filed or raised with regard to such patents. This raises significant doubts about the compatibility of how the ‘long arm’ is applied in the Unified Patent Court system, given its own Rules of Procedure.
03 Mar, 2026 
PUBLICATION
26 Feb, 2026
Pharma & Healthcare No. 47
The newsletter covers the main developments in Pharma & Healthcare legislation and case law.
26 Feb, 2026
PUBLICATION
09 Feb, 2026
Notarial enforcement of pledges. Is Article 1872 of the Civil Code mandatory? In what sense?
The clause agreed upon must comply, for greater certainty, with the provisions of the new judicial enforcement procedure. It will be necessary to agree on an appraised value, which is not required in Article 1872 CC, because otherwise the award would be similar to a ‘forfeiture proviso’ (pactum commissorium), which the Civil Code neutralised with the drastic imposition of extinguishment of the debt in its entirety.
09 Feb, 2026
PUBLICATION
06 Feb, 2026
Automotive and Sustainable Mobility No. 29
Summary of legislative and jurisprudential developments relating to the automotive sector.
06 Feb, 2026
PUBLICATION
27 Jan, 2026
Jurisdiction of national courts of States party to the Agreement on a Unified Patent Court in respect of actions relating to classic European patents during the transitional period
During the transitional period of the Agreement on a Unified Patent Court, national courts retain jurisdiction to hear cases concerning classic European patents, without the need for the proprietor to have exercised the opt-out option, i.e. without the need to have excluded the jurisdiction of the Unified Patent Court over such patents. However, the Venice Court ruling discussed here considers that national courts may only be used if the opt-out has been exercised, contradicting the provisions of Article 83 of the Agreement.
27 Jan, 2026
PUBLICATION
21 Jan, 2026
Incompatibility between practising a healthcare profession and having a pecuniary interest in the manufacture or sale of medicinal products or medical devices
Royal Legislative Decree 1/2015, of 24 July, approving the recast version of the Medicinal Products and Medical Devices (Guarantees and Rational Use) Act, prohibits healthcare professionals with prescribing powers from having a direct pecuniary interest in activities related to medicines. This prohibition does not extend to indirect interests, as distinguished in Article 4 of said legislative decree. Judgment no. 483/2025 of the High Court of Justice of the Basque Country concludes that mere membership of a group of companies does not entail incompatibility if each entity retains real autonomy.
21 Jan, 2026
PUBLICATION
15 Jan, 2026
Excessive extension of the Bolar clause in the 'pharmaceutical legislative package'
The Bolar clause allows studies and trials necessary to obtain marketing authorisations for medicinal products to be carried out without infringing patents. Its scope has grown during the passage of the pharmaceutical legislative package, incorporating more actors and more activities, to include participation in public tenders before the patent expires. This extension raises questions about compatibility with the TRIPS Agreement, which only allows limited exceptions to patent rights. Participation in tenders could be considered an offer to sell, thus violating the limits set by that agreement.
15 Jan, 2026
PUBLICATION
15 Dec, 2025
Direct harm due to de facto expulsion: Article 241 of the Companies Act (Supreme Court Judgment, First Chamber, 22 October 2025)
This paper analyses the subject matter scope of application of a ‘director liability to shareholder claim’ (claim for payment of damages filed by a shareholder against a company director). Although, as a general rule, shareholders cannot claim compensation for the harm caused to their share in a company’s estate, compensation for de facto expulsions or harm to liquidating dividends may be awarded through a director liability to shareholder claim.
15 Dec, 2025
PUBLICATION
11 Dec, 2025
Do consumer associations have universal locus standi? On the subject of two orders issued by the Provincial Court of Barcelona regarding the ‘car cartel’
The universal standing of consumer associations has no legal basis and creates perverse effects.
11 Dec, 2025